Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.
Full Year 2024 Results Key Financial Results Revenue: US$16.7b (up 18% from FY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback